You're in the right place! Welcome to our newly updated ESC website.
Start exploring or use our powerful new search engine to find what you need. 

The Revolution in Pharmacotherapy: From Herbs to Pills to Antibodies and Nucleic Acids

31 Jan 2024 - 01 Feb 2024
+ 2024-01-31T10:00 2024-02-01T17:00 Europe/Paris The Revolution in Pharmacotherapy: From Herbs to Pills to Antibodies and Nucleic Acids
Add to calendar 2024-01-31T10:00 2024-02-01T17:00 Europe/Paris The Revolution in Pharmacotherapy: From Herbs to Pills to Antibodies and Nucleic Acids
CRT Onsite

Objectives of the meeting  

Historical Development of Pharmacotherapy

Pharmacotherapy started with herbs that were sometimes useful, but often toxic. Then we moved to pills, where the active ingredient (for example for digitalis, the steroid) was purified and a more precise dosage and avoidance of side-effects, as much as possible, became a reality. Pharmacotherapy today relies on pills containing a vast number of molecules interfering with cell surface receptors (e.g. a/b-receptors, AT1-receptors, P2Y12-receptors), enzymes (ACE, neprilysin), ion/metabolite transporters (SGLT2) and other pathways for the treatment of blood pressure, lipids, diabetes, coronary artery disease and heart failure. More recently, antibodies interfering with crucial proteins have become clinical practice, after rheumatology (infliximab, adalimumab, among others) now also in cardiology with antibodies against PCSK9.

Final Programme

DAY 1: 31 January 2024 - 14:00-18:15
DAY 2: 01 February 2024 - 08:00 - 12:45

  • 08:00 - 12:45 - SESSION 2 – From Antibodies to Nucleotid Acids and beyond (Moderated by: Ulf Landmesser and Jürgen Prochaska (Boehringer Ingelheim Pharmaceuticals Inc))

  • 08:00-08:30 - Cardiovascular Gene Therapy - Efficient gene delivery to the heart? What are the best targets? - Roger Hajjar

  • 08:30-09:00 - ASO/siRNa vs. antibodies for TTR amyloid heart disease - Mathew Maurer

  • 09:00-09:30 - miRNAs as therapeutic tools - Thomas Thum

  • 09:30-10:00 - CRISPR-Cas9: From treatment to cure? - Sekar Kathiresan (Verve Therapeutics)

  • 10:00-10:15 - Coffee break

  • 10:15-11:15 - BREAKOUT SESSIONS 2: From Treatment to cure - 60 min

    • Group 1: Compliance with the new tools - Lead: Francesco Cosentino, Rapporteur: Ricardo Rocha (Intellia Therapeutics)
    • Group 2: miRNAs - Lead: Christopher O’Donnell (Novartis), Rapporteur: Tomasz Guzik
    • Group 3: How to target the heart or the kidney: in search of novel strategies - Lead: Benjamin Meder, Rapporteur: Lothar Roessig (ASKBIO/Bayer)

  • 11:15-11:25 - Report from breakout session 1 – 10 mins - Rapporteur: Ricardo Rocha (Intellia Therapeutics)

  • 11:25-11:35 - Report from breakout session 2 – 10 mins - Rapporteur: Tomasz Guzik

  • 11:35-11:45 - Report from breakout session 3 – 10 mins - Rapporteur: Lothar Roessig (ASKBIO/Bayer)

  • 11:45-12:05 - Patient’s perspectives on nucleoid acid therapy - Mattias Van Heetvelde (ESC Patient Forum)

  • 12:05-12:35 - Ethical issues of genetic therapeutic tools - Julian März

  • 12:35-12:45 - Wrap-up, conclusions, next steps for a publication - Chairpersons

  • END OF DAY 2

  • 13:00 - Buffet lunch and departures

Nucleotid acids as novel therapeutics

A true revolution of pharmacotherapy took place with the discovery of RNA interference by Andrew Fire and Craig Mello, Nobel Prize Laureates in 2006, as well as the use of antisense oligonucleotides. These molecules no longer interfere with surface receptors or enzymes in the circulation or in cardiovascular tissue, but rather prevent the translation of messenger RNA into a target protein (Figure 1). When combined with tags interfering with specific surface receptors (e.g. GalNac with Asialoglycoprotein receptors on hepatocytes)  these nucleic acids can be made highly organ and tissue specific and often have a long duration of action (up to >6 months).

Figure 1: Mechanisms of action of RNA interference in the liver. The double strand RNA with a nucleotid sequence complementory to the target mRNA is tagged with N-acetylgalactosamine (GalNac) and binds speficially to the Asialoglycoprotein receptor (ASGR) that is only expressed in liver cells. After internalisation, it binds in the cytoplasm to the RNA-Induced Silencing Complex (RISC) and prevents translation of the transcript to the target protein for prolonged periods of time. (from Landmesser U, …Luzscher TF. Eur. Heart J. 2020;44:3848-3899).

CRISPR-Cas9: From treatment to cure

Figure 2: The discovery of geneediting with CRISPR-Cas9

Of note, the future holds even more promising tools; indeed, with the discovery of the gene scissor, CRISPR-Cas9, by Emmanuelle Charpentier and Jennifer Doudna, Nobel Laureates  in 2020 (Figure 2) gene editing has become possible with a single treatment in a lifetime for pa-tients with various medical conditions. Indeed, in Amyloidosis already a few patients have been successfully treated and as for lipids, the technique has been successfully used in primates.

These new developments in pharmacotherapy bring enormous opportunities, but also questions as regards their safety and sustainability, but they will certainly change medicine as it has been practiced in the past.

Objectives of the CRT meeting: To discuss the basics of this new pharmacotherapy, its current application and future perspectives, as well as important safety and ethical issues associated with it. Furthermore, the goal is to involve the European Medical Agency (and possibly the Federal Drug Administration in the USA) to discuss registration issues with these new technologies, and in particular, as regards the advent of CRISPR-Cas9.

Related Reading

From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases
European Heart Journal
From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases
29 Apr 2020 - 02:00
View Details

Session Recording

Day 1

Day 2

Academic Chairpersons

Photo
Professor Thomas Felix Luescher

ESC President-elect and ESC Chair of the CRT

Photo
Professor Ulf Landmesser

Industry Chairpersons

Doctor Ricardo Rocha

Intellia Therapeutics

Professor Juergen Prochaska

Boehringer Ingelheim Pharmaceuticals Inc

Doctor Andres Laguna Fernandez

Novartis

Photo
Doctor Alexandra Goncalves

BMS (Industry Chair of the CRT)

Biographies

Prof. Thomas F. LÜSCHER, UK.pdf (PDF)
Prof. Alexandra GONCALVES, BMS.pdf (PDF)
Prof. Ulf LANDMESSER, Germany.pdf (PDF)
Dr. Andres LAGUNA, Novartis.pdf (PDF)
Dr. Jürgen PROCHASKA, Boehringer Ingelheim Pharmaceuticals Inc.pdf (PDF)
Dr. Mathew S. MAURER, USA.pdf (PDF)
Prof. Anders HIMMELMANN, AstraZeneca.pdf (PDF)
Dr. Christopher O-DONNELL, Novartis Pharma.pdf (PDF)
Dr. Sekar KATHIRESAN, Verve Therapeutics.pdf (PDF)
Dr. Julian MÄRZ, Switzerland.pdf (PDF)
Prof. Thomas THUM, Germany.pdf (PDF)
Prof. Benjamin Meder.pdf (PDF)
Prof. Roger HAJJAR, USA.pdf (PDF)
Dr. Lothar ROESSIG, AskBio.pdf (PDF)
Prof. Lale TOKGÖZOĞLU, Turkey.pdf (PDF)
Dr. Anna TAVRIDOU, EMA.pdf (PDF)
Dr. Gabriella PASSACQUALE, EMA.pdf (PDF)
Mr. Mattias VAN HEETVELDE, Belgium.pdf (PDF)
Prof. Francesco COSENTINO, Sweden.pdf (PDF)
Dr Clemens Mittmann, Germany.pdf (PDF)